牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 480 shares of common stock on 02/20/2024, with an aggregate market value of $201,979.20. The shares to be sold were recently acquired on 02/17/2024, as part of compensation in the form of 240 performance shares and 240 shares from restricted stock vesting, both issued by the company. This transaction follows a previous sale of 314 shares by Tatsis in the past three months, which grossed $131,955.36. The notice for the upcoming sale was filed on the same day as the planned sale, with the instruction for this transaction having been adopted on 05/09/2023.
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 480 shares of common stock on 02/20/2024, with an aggregate market value of $201,979.20. The shares to be sold were recently acquired on 02/17/2024, as part of compensation in the form of 240 performance shares and 240 shares from restricted stock vesting, both issued by the company. This transaction follows a previous sale of 314 shares by Tatsis in the past three months, which grossed $131,955.36. The notice for the upcoming sale was filed on the same day as the planned sale, with the instruction for this transaction having been adopted on 05/09/2023.
Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月20日出售480股普通股，總市值爲201,979.20美元。擬出售的股票最近於2024年2月17日被收購，作爲補償的一部分，公司發行了240股績效股票和240股限制性股票歸屬股票。該交易是在塔西斯在過去三個月中出售314股股票之後進行的，總收入爲131,955.36美元。即將進行的出售通知是在計劃出售的同一天提交的，該交易的指示已於2023年9月5日通過。
Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月20日出售480股普通股，總市值爲201,979.20美元。擬出售的股票最近於2024年2月17日被收購，作爲補償的一部分，公司發行了240股績效股票和240股限制性股票歸屬股票。該交易是在塔西斯在過去三個月中出售314股股票之後進行的，總收入爲131,955.36美元。即將進行的出售通知是在計劃出售的同一天提交的，該交易的指示已於2023年9月5日通過。
有用
沒用